Selecta is actively seeking partnerships including in-licensing and out-licensing opportunities that would be consistent with the portfolio strategy.
Out-licensing and research collaboration opportunities exist for Synthetic Vaccine Particles (SVP™) and our tolerogenic Dendritic Cell (itDC) programs. Areas of interest include vaccines and immunotherapies including infections, cancer, respiratory, autoimmunity, allergies, transplantation, and orphan indications.
Selecta is also looking for in-licensing opportunities that are coordinated with our Moscow, Russia offices. Selecta Russia has access to development capabilities that enable us to efficiently conduct human proof of concept studies. We consider phase 1 and phase 2 assets preferentially in the therapeutic areas of inflammation, immunology, cancer, respiratory, and infection.
Sanofi and Selecta are collaborating to develop up to three tolerogenic immunotherapies in the area of allergies.
Click here to learn more about this collaboration.
In 2011, Selecta was awarded a subcontract by Science Applications International Corporation (SAIC) to develop a targeted antigen-specific synthetic vaccine particle product for malaria. Part of a larger US Federal Government initiative to develop and commercialize novel therapeutics and vaccines for malaria, Selecta's development efforts will be funded under SAIC's prime contract (number N01.AI.05421) with the National Institutes of Allergy and Infectious Diseases' (NIAID)Division of Microbiology and Infectious Diseases (DMID), which is part of the National Institutes of Health. Click here to learn more about this collaboration.
In 2010, Selecta was awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of a therapeutic vaccine for the treatment of smoking cessation and relapse prevention. Click here to learn more about this collaboration.
In 2011, Selecta formed a research collaboration with The Juvenile Diabetes Research Foundation (JDRF) to support the development of targeted synthetic vaccines for the induction of antigen-specific immune tolerance for treatment of patients with juvenile diabetes (type 1 or insulin dependent diabetes mellitus), an autoimmune disorder. Click here to learn more about this collaboration.
For further information about Selecta and the company's partnering and collaboration opportunities, please contact email@example.com.